上咽頭癌(NPC)と呼ばれる種類の癌を治療するために、新薬ニボルマブを化学療法薬と組み合わせて使用する研究
新たに診断された上咽頭癌(NPC)に対するゲムシタビン、シスプラチン、ニボルマブによる化学免疫療法を用いた第2相試験
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Researchers want to find out what effects, good and/or bad, adding nivolumab to chemotherapy has on patients with newly diagnosed NPC. In addition, they want to find out if children with NPC may be treated with less radiation therapy and whether this decreases the side effects of therapy.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
- 他の:Quality-of-Life Assessment
- 薬:Cisplatin
- 手順:Biospecimen Collection
- 手順:Computed Tomography
- 手順:Magnetic Resonance Imaging
- 他の:Questionnaire Administration
- 手順:Echocardiography Test
- 手順:Multigated Acquisition Scan
- 手順:Positron Emission Tomography
- 生物学的:Nivolumab
- 薬:Gemcitabine
- 手順:Biopsy Procedure
- 手順:Chest Radiography
- 他の:Electronic Health Record Review
- 放射線:Radiation Therapy
- 他の:Fluciclovine F18
- 手順:X-Ray Imaging
詳細な説明
PRIMARY OBJECTIVE:
I. To evaluate safety of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC) by determining the rate of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher immune related adverse events (irAEs).
SECONDARY OBJECTIVES:
I. To estimate the 2-year event-free survival (EFS) of children, adolescents and young adults with NPC who are treated with induction chemoimmunotherapy (CIT), followed by consolidation chemoradioimmunotherapy (CRIT, cisplatin, nivolumab and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy.
II. To evaluate the objective response rate (ORR) including complete responders and partial responders (complete response [CR] + partial response [PR]) of neoadjuvant CIT.
III. To evaluate feasibility of combining chemotherapy (cisplatin and gemcitabine) with an anti-PD1 immune checkpoint inhibitor (nivolumab) in children, adolescents and young adults with nasopharyngeal carcinoma (NPC).
IV. To evaluate the cumulative incidence of local and distant relapse.
EXPLORATORY OBJECTIVES:
I. To estimate 5-year EFS and overall survival (OS) of children with NPC who are treated with induction CIT followed by consolidation CRIT, and nivolumab maintenance therapy.
II. To compare response assessed by fludeoxyglucose F18 (FDG) positron emission tomography (PET) versus magnetic resonance imaging (MRI).
III. To determine treatment outcomes for patients treated with radiation per protocol versus (vs) deviation.
IV. To evaluate outcomes comparing patients receiving intensity modulated radiation therapy (IMRT) to proton therapy.
V. To objectively measure both acute and long-term toxicity including immune related adverse events and radiation late effects.
VI. To evaluate swallowing dysfunction using patient reported outcome (PRO) measures for children and adults throughout the protocol for up to 5 years.
VII. To evaluate quality of life (QOL) using Patient-Reported Outcomes Measurement Information System (PROMIS) multidimensional questionnaire throughout the protocol for up to 5 years.
VIII. To correlate the lymphocyte to monocyte ratio on complete blood counts (CBCs) with treatment response and outcomes.
IX. To collect and bank specimens (including tumor and blood) for future research studies.
X. To compare dental x-rays in patients prior to radiation and 1 year post radiation to evaluate for dental caries and bone health.
OUTLINE:
INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle, gemcitabine IV over 30 minutes on days 1 and 8 of each cycle, and cisplatin IV over 3-6 hours on day 1 of each cycle. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and cisplatin IV over 3-6 hours on day 1 of cycles 1-2. Treatment repeats every 21 days for 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive concurrent radiation therapy on trial.
MAINTENANCE THERAPY: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
Patients also undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) during screening and as clinically indicated on trial. Patients undergo MRI, FDG PET, and computed tomography (CT) throughout the trial and chest x-ray during follow-up. Patients also undergo dental x-ray imaging on the trial. Patients may optionally undergo tissue biopsy and blood sample collection during screening and on trial.
After completion of study treatment, patients are followed up every 3 months for 12 months, every 6 months until 24 months off therapy, and then yearly until 5 years off therapy.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- 募集
- Children's Hospital of Alabama
-
コンタクト:
- Site Public Contact
- 電話番号:205-638-9285
- メール:oncologyresearch@peds.uab.edu
-
主任研究者:
- Jamie M. Aye
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85016
- 募集
- Phoenix Childrens Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:602-546-0920
-
主任研究者:
- Alok K. Kothari
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72202-3591
- 募集
- Arkansas Children's Hospital
-
主任研究者:
- Michael W. Bishop
-
コンタクト:
- Site Public Contact
- 電話番号:501-364-7373
-
-
California
-
Downey、California、アメリカ、90242
- 募集
- Kaiser Permanente Downey Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:626-564-3455
-
主任研究者:
- Robert M. Cooper
-
Loma Linda、California、アメリカ、92354
- 募集
- Loma Linda University Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:909-558-4050
-
主任研究者:
- Albert Kheradpour
-
Los Angeles、California、アメリカ、90027
- 募集
- Children's Hospital Los Angeles
-
主任研究者:
- Rachana Shah
-
コンタクト:
- Site Public Contact
- 電話番号:323-361-4110
-
Madera、California、アメリカ、93636
- 募集
- Valley Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:559-353-3000
- メール:Research@valleychildrens.org
-
主任研究者:
- Ruetima Titapiwatanakun
-
Oakland、California、アメリカ、94611
- 募集
- Kaiser Permanente-Oakland
-
コンタクト:
- Site Public Contact
- 電話番号:877-642-4691
- メール:Kpoct@kp.org
-
主任研究者:
- Aarati V. Rao
-
Oakland、California、アメリカ、94609
- 募集
- UCSF Benioff Children's Hospital Oakland
-
主任研究者:
- Jennifer G. Michlitsch
-
コンタクト:
- Site Public Contact
- 電話番号:510-428-3264
- メール:PedOncRschOAK@ucsf.edu
-
San Diego、California、アメリカ、92123
- 募集
- Rady Children's Hospital - San Diego
-
コンタクト:
- Site Public Contact
- 電話番号:858-966-5934
-
主任研究者:
- William D. Roberts
-
San Francisco、California、アメリカ、94158
- 募集
- UCSF Medical Center-Mission Bay
-
コンタクト:
- Site Public Contact
- 電話番号:877-827-3222
- メール:cancertrials@ucsf.edu
-
主任研究者:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Children's Hospital Colorado
-
主任研究者:
- Navin R. Pinto
-
コンタクト:
- Site Public Contact
- 電話番号:303-764-5056
- メール:josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford、Connecticut、アメリカ、06106
- 募集
- Connecticut Children's Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:860-545-9981
-
主任研究者:
- Michael S. Isakoff
-
-
Delaware
-
Wilmington、Delaware、アメリカ、19803
- 募集
- Alfred I duPont Hospital for Children
-
コンタクト:
- Site Public Contact
- 電話番号:302-651-5572
- メール:Allison.bruce@nemours.org
-
主任研究者:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C.、District of Columbia、アメリカ、20010
- 募集
- Children's National Medical Center
-
主任研究者:
- Jeffrey S. Dome
-
コンタクト:
- Site Public Contact
- 電話番号:202-476-2800
- メール:OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Gainesville、Florida、アメリカ、32610
- 募集
- UF Health Cancer Institute - Gainesville
-
コンタクト:
- Site Public Contact
- 電話番号:352-273-8010
- メール:cancer-center@ufl.edu
-
主任研究者:
- Brian Stover
-
Jacksonville、Florida、アメリカ、32207
- 募集
- Nemours Children's Clinic-Jacksonville
-
コンタクト:
- Site Public Contact
- 電話番号:302-651-5572
- メール:Allison.bruce@nemours.org
-
主任研究者:
- Sridhi Patel
-
Miami、Florida、アメリカ、33155
- 募集
- Nicklaus Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:888-624-2778
-
主任研究者:
- Ziad A. Khatib
-
Orlando、Florida、アメリカ、32806
- 募集
- Arnold Palmer Hospital for Children
-
コンタクト:
- Site Public Contact
- 電話番号:321-841-5357
- メール:Jennifer.spinelli@orlandohealth.com
-
主任研究者:
- Zhongbo Hu
-
Orlando、Florida、アメリカ、32827
- 募集
- Nemours Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:302-651-5572
- メール:Allison.bruce@nemours.org
-
主任研究者:
- Sridhi Patel
-
Pensacola、Florida、アメリカ、32504
- 募集
- Nemours Children's Clinic - Pensacola
-
コンタクト:
- Site Public Contact
- メール:helpdesk@childrensoncologygroup.org
-
主任研究者:
- Jeffrey H. Schwartz
-
Tampa、Florida、アメリカ、33607
- 募集
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
コンタクト:
- Site Public Contact
- 電話番号:813-357-0849
- メール:jennifer.manns@baycare.org
-
主任研究者:
- Don E. Eslin
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- 募集
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
主任研究者:
- Sarah G. Mitchell
-
コンタクト:
- Site Public Contact
- 電話番号:404-785-0232
- メール:Olivia.Floyd@choa.org
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- 募集
- Lurie Children's Hospital-Chicago
-
主任研究者:
- Amy L. Walz
-
コンタクト:
- Site Public Contact
- 電話番号:773-880-4562
-
Chicago、Illinois、アメリカ、60637
- 一時停止
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- 募集
- Riley Hospital for Children
-
コンタクト:
- Site Public Contact
- 電話番号:800-248-1199
-
主任研究者:
- Marissa Just
-
-
Kentucky
-
Lexington、Kentucky、アメリカ、40536
- まだ募集していません
- University of Kentucky/Markey Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:859-257-3379
-
主任研究者:
- James T. Badgett
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70118
- 募集
- Children's Hospital New Orleans
-
主任研究者:
- Maria C. Velez-Yanguas
-
コンタクト:
- Site Public Contact
- 電話番号:504-894-5377
-
-
Maine
-
Scarborough、Maine、アメリカ、04074
- 募集
- Maine Children's Cancer Program
-
主任研究者:
- Aaron R. Weiss
-
コンタクト:
- Site Public Contact
- 電話番号:207-396-8670
- メール:clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:410-955-8804
- メール:jhcccro@jhmi.edu
-
主任研究者:
- Robyn D. Gartrell
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute
-
主任研究者:
- Allison F. O'Neill
-
コンタクト:
- Site Public Contact
- 電話番号:877-442-3324
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49503
- 募集
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:616-391-1230
- メール:crcwm-regulatory@crcwm.org
-
主任研究者:
- Kathleen Y. Butler
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- 募集
- Mayo Clinic in Rochester
-
コンタクト:
- Site Public Contact
- 電話番号:855-776-0015
-
主任研究者:
- Peter Schoettler
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- 募集
- University of Mississippi Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:601-815-6700
-
主任研究者:
- Amanda Strobel
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- 募集
- Children's Mercy Hospitals and Clinics
-
主任研究者:
- Keith J. August
-
コンタクト:
- Site Public Contact
- 電話番号:816-302-6808
- メール:COGResearchGroup@cmh.edu
-
St Louis、Missouri、アメリカ、63110
- 募集
- Washington University School of Medicine
-
コンタクト:
- Site Public Contact
- 電話番号:800-600-3606
- メール:info@siteman.wustl.edu
-
主任研究者:
- Frederick S. Huang
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68114
- 募集
- Children's Hospital and Medical Center of Omaha
-
コンタクト:
- Site Public Contact
- 電話番号:402-955-3949
-
主任研究者:
- Jill C. Beck
-
Omaha、Nebraska、アメリカ、68198
- 募集
- University of Nebraska Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:402-559-6941
- メール:unmcrsa@unmc.edu
-
主任研究者:
- Jill C. Beck
-
-
New Jersey
-
Hackensack、New Jersey、アメリカ、07601
- 募集
- Hackensack University Medical Center
-
主任研究者:
- Katharine Offer
-
コンタクト:
- Site Public Contact
- 電話番号:551-996-2897
-
Neptune City、New Jersey、アメリカ、07753
- 募集
- Jersey Shore Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:732-776-4240
-
主任研究者:
- Katharine Offer
-
New Brunswick、New Jersey、アメリカ、08903
- 募集
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
主任研究者:
- Scott Moerdler
-
コンタクト:
- Site Public Contact
- 電話番号:732-235-8675
-
Newark、New Jersey、アメリカ、07112
- 募集
- Newark Beth Israel Medical Center
-
主任研究者:
- Scott Moerdler
-
コンタクト:
- Site Public Contact
- 電話番号:973-926-7230
- メール:Christine.Kosmides@rwjbh.org
-
主任研究者:
- Teena Bhatla
-
-
New York
-
Albany、New York、アメリカ、12208
- 募集
- Albany Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:518-262-5513
-
主任研究者:
- Lauren R. Weintraub
-
The Bronx、New York、アメリカ、10467
- 募集
- Montefiore Medical Center - Moses Campus
-
コンタクト:
- Site Public Contact
- 電話番号:718-379-6866
- メール:eskwak@montefiore.org
-
主任研究者:
- Alice Lee
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28203
- 募集
- Carolinas Medical Center/Levine Cancer Institute
-
コンタクト:
- Site Public Contact
- 電話番号:800-804-9376
-
主任研究者:
- Joel A. Kaplan
-
Durham、North Carolina、アメリカ、27710
- 募集
- Duke University Medical Center
-
主任研究者:
- Jessica M. Sun
-
コンタクト:
- Site Public Contact
- 電話番号:888-275-3853
-
Greenville、North Carolina、アメリカ、27834
- 募集
- East Carolina University
-
コンタクト:
- Site Public Contact
- 電話番号:252-744-1015
- メール:eubankss@ecu.edu
-
主任研究者:
- Andrea R. Whitfield
-
Winston-Salem、North Carolina、アメリカ、27157
- 募集
- Wake Forest University Health Sciences
-
コンタクト:
- Site Public Contact
- 電話番号:336-713-6771
-
主任研究者:
- Sarah Supples
-
-
North Dakota
-
Fargo、North Dakota、アメリカ、58122
- 募集
- Sanford Broadway Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:701-323-5760
- メール:OncologyClinicalTrialsFargo@sanfordhealth.org
-
主任研究者:
- Samuel J. Milanovich
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45229
- 募集
- Cincinnati Children's Hospital Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:513-636-2799
- メール:cancer@cchmc.org
-
主任研究者:
- Brian K. Turpin
-
Cleveland、Ohio、アメリカ、44106
- 募集
- Rainbow Babies and Childrens Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:216-844-5437
-
主任研究者:
- Duncan S. Stearns
-
Columbus、Ohio、アメリカ、43205
- 募集
- Nationwide Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:614-722-6039
- メール:Melinda.Triplet@nationwidechildrens.org
-
主任研究者:
- Mark A. Ranalli
-
Dayton、Ohio、アメリカ、45404
- 募集
- Dayton Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:800-228-4055
-
主任研究者:
- Jordan M. Wright
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73104
- 募集
- University of Oklahoma Health Sciences Center
-
コンタクト:
- Site Public Contact
- 電話番号:405-271-8777
- メール:ou-clinical-trials@ouhsc.edu
-
主任研究者:
- Rene Y. McNall-Knapp
-
-
Pennsylvania
-
Allentown、Pennsylvania、アメリカ、18103
- 募集
- Lehigh Valley Hospital-Cedar Crest
-
コンタクト:
- Site Public Contact
- 電話番号:610-402-9543
- メール:Morgan_M.Horton@lvhn.org
-
主任研究者:
- Jacob A. Troutman
-
Hershey、Pennsylvania、アメリカ、17033
- 募集
- Penn State Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:717-531-6012
-
主任研究者:
- Lisa M. McGregor
-
Philadelphia、Pennsylvania、アメリカ、19104
- 募集
- Children's Hospital of Philadelphia
-
コンタクト:
- Site Public Contact
- 電話番号:267-425-5544
- メール:CancerTrials@email.chop.edu
-
主任研究者:
- Theodore W. Laetsch
-
Pittsburgh、Pennsylvania、アメリカ、15224
- 募集
- Children's Hospital of Pittsburgh of UPMC
-
コンタクト:
- Site Public Contact
- 電話番号:412-692-8570
- メール:jean.tersak@chp.edu
-
主任研究者:
- Brittani K. Seynnaeve
-
-
South Carolina
-
Columbia、South Carolina、アメリカ、29203
- 募集
- Prisma Health Richland Hospital
-
主任研究者:
- Stuart L. Cramer
-
コンタクト:
- Site Public Contact
- 電話番号:864-522-4317
- メール:Kim.Williams3@prismahealth.org
-
Greenville、South Carolina、アメリカ、29605
- 募集
- BI-LO Charities Children's Cancer Center
-
主任研究者:
- Aniket Saha
-
コンタクト:
- Site Public Contact
- 電話番号:864-522-4317
- メール:Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls、South Dakota、アメリカ、57117-5134
- 募集
- Sanford USD Medical Center - Sioux Falls
-
コンタクト:
- Site Public Contact
- 電話番号:605-312-3320
- メール:OncologyClinicalTrialsSF@SanfordHealth.org
-
主任研究者:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105
- 募集
- Saint Jude Children's Research Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:888-226-4343
- メール:referralinfo@stjude.org
-
主任研究者:
- Catherine G. Lam
-
Nashville、Tennessee、アメリカ、37232
- 募集
- Vanderbilt University/Ingram Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:800-811-8480
-
主任研究者:
- Scott C. Borinstein
-
Nashville、Tennessee、アメリカ、37203
- 募集
- The Children's Hospital at TriStar Centennial
-
コンタクト:
- Site Public Contact
- 電話番号:615-342-1919
-
主任研究者:
- Clinton M. Carroll
-
-
Texas
-
Austin、Texas、アメリカ、78723
- 募集
- Dell Children's Medical Center of Central Texas
-
コンタクト:
- Site Public Contact
- 電話番号:512-628-1902
- メール:TXAUS-DL-SFCHemonc.research@ascension.org
-
主任研究者:
- Shannon M. Cohn
-
Dallas、Texas、アメリカ、75390
- 募集
- UT Southwestern/Simmons Cancer Center-Dallas
-
コンタクト:
- Site Public Contact
- 電話番号:214-648-7097
- メール:canceranswerline@UTSouthwestern.edu
-
主任研究者:
- Avanthi T. Shah
-
Fort Worth、Texas、アメリカ、76104
- 募集
- Cook Children's Medical Center
-
コンタクト:
- Site Public Contact
- 電話番号:682-885-2103
- メール:CookChildrensResearch@cookchildrens.org
-
主任研究者:
- Chelsee Greer
-
Houston、Texas、アメリカ、77030
- 募集
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:713-798-1354
- メール:burton@bcm.edu
-
主任研究者:
- Mehmet F. Okcu
-
Houston、Texas、アメリカ、77030
- 募集
- UT MD Anderson Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:866-632-6789
- メール:askmdanderson@mdanderson.org
-
主任研究者:
- Najat C. Daw
-
San Antonio、Texas、アメリカ、78207
- 募集
- Children's Hospital of San Antonio
-
コンタクト:
- Site Public Contact
- 電話番号:210-704-2894
- メール:bridget.medina@christushealth.org
-
主任研究者:
- Julie Voeller
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22908
- 募集
- University of Virginia Cancer Center
-
コンタクト:
- Site Public Contact
- 電話番号:434-243-6303
- メール:uvacancertrials@hscmail.mcc.virginia.edu
-
主任研究者:
- Brian C. Belyea
-
Norfolk、Virginia、アメリカ、23507
- 募集
- Children's Hospital of The King's Daughters
-
コンタクト:
- Site Public Contact
- 電話番号:757-668-7243
- メール:CCBDCresearch@chkd.org
-
主任研究者:
- Melissa S. Mark
-
Richmond、Virginia、アメリカ、23298
- 募集
- VCU Massey Comprehensive Cancer Center
-
主任研究者:
- Madhu S. Gowda
-
コンタクト:
- Site Public Contact
- 電話番号:804-628-6430
- メール:CTOclinops@vcu.edu
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- 募集
- Seattle Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:866-987-2000
-
主任研究者:
- Sarah E. Leary
-
Tacoma、Washington、アメリカ、98405
- 募集
- Mary Bridge Children's Hospital and Health Center
-
コンタクト:
- Site Public Contact
- 電話番号:253-403-1461
- メール:research@multicare.org
-
主任研究者:
- Robert G. Irwin
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- 募集
- Children's Hospital of Wisconsin
-
主任研究者:
- Angela Steineck
-
コンタクト:
- Site Public Contact
- 電話番号:414-955-4727
- メール:MACCCTO@mcw.edu
-
-
-
-
New South Wales
-
Hunter Regional Mail Centre、New South Wales、オーストラリア、2310
- 募集
- John Hunter Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:(02) 4985 5180
-
主任研究者:
- Kristy McCarthy
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T3B 6A8
- 募集
- Alberta Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:403-220-6898
- メール:research4kids@ucalgary.ca
-
主任研究者:
- Victor A. Lewis
-
Edmonton、Alberta、カナダ、T6G 2B7
- 募集
- University of Alberta Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:780-407-8798
- メール:pedsoncologyresearch@ahs.ca
-
主任研究者:
- Sarah J. McKillop
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 1X8
- 募集
- Hospital for Sick Children
-
コンタクト:
- Site Public Contact
- 電話番号:416-813-7654
- メール:ask.CRS@sickkids.ca
-
主任研究者:
- Avram E. Denburg
-
-
Quebec
-
Montreal、Quebec、カナダ、H3H 1P3
- 募集
- The Montreal Children's Hospital of the MUHC
-
コンタクト:
- Site Public Contact
- 電話番号:514-412-4445
- メール:info@thechildren.com
-
主任研究者:
- Stephanie Mourad
-
Montreal、Quebec、カナダ、H3T 1C5
- 募集
- Centre Hospitalier Universitaire Sainte-Justine
-
主任研究者:
- Monia Marzouki
-
コンタクト:
- Site Public Contact
- 電話番号:514-345-4931
- メール:yvan.samson@umontreal.ca
-
Sherbrooke、Quebec、カナダ、J1H 5N4
- 募集
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
コンタクト:
- Site Public Contact
- 電話番号:819-820-6480
- メール:crcinformation.chus@ssss.gouv.qc.ca
-
主任研究者:
- Stephanie Vairy
-
-
-
-
-
Christchurch、ニュージーランド、8011
- 募集
- Christchurch Hospital
-
主任研究者:
- Tristan Pettit
-
コンタクト:
- Site Public Contact
- 電話番号:03 364 0640
-
-
Auckland
-
Grafton、Auckland、ニュージーランド、1145
- 募集
- Starship Children's Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:0800 728 436
-
主任研究者:
- Leander D. Timothy
-
-
-
-
-
San Juan、プエルトリコ、00926
- 募集
- University Pediatric Hospital
-
コンタクト:
- Site Public Contact
- 電話番号:787-474-0333
-
主任研究者:
- Maria E. Echevarria
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must be ≤ 21 years of age at the time of study enrollment
-
Newly diagnosed American Joint Committee on Cancer (AJCC) (8th edition) stage II-IV nasopharyngeal carcinoma (NPC)
- Patients must have had histologic verification of the malignancy at original diagnosis
- Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have had histologic verification of the malignancy at original diagnosis
-
Although submission of tumor tissue for the molecular characterization initiative is not required for eligibility, it is strongly recommended
-
Patients must have a Lansky (for patients ≤ 16 years of age) or Karnofsky (for patients > 16 years of age) performance status score of ≥ 60%
-
Peripheral absolute neutrophil count (ANC) ≥ 1000/uL (within 7 days prior to start of protocol therapy)
-
Platelet count ≥ 100,000/uL (transfusion independent) (within 7 days prior to start of protocol therapy)
-
Creatinine clearance or radioisotope glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m^2 or (within 7 days prior to start of protocol therapy)
-
A serum creatinine based on age/sex (within 7 days prior to start of protocol therapy) Age: Maximum serum creatinine (mg/dL)
1 month to < 6 months: 0.4 mg/dL (male); 0.4 mg/dL (female) 6 months to < 1 year: 0.5 mg/dL (male); 0.5 mg/dL (female)
- to < 2 years: 0.6 mg/dL (male); 0.6 mg/dL (female)
- to < 6 years: 0.8 mg/dL (male); 0.8 mg/dL (female)
6 to < 10 years 1 mg/dL (male); 1 mg/dL (female) 10 to <13 years: 1.2 mg/dL (male); 1.2 mg/dL (female) 13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female) â ¥ 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age, and (within 7 days prior to start of protocol therapy)
-
Serum glutamic-pyruvic transaminase (SGPT) (alanine aminotransferase [ALT]) ≤ 135 U/L* (within 7 days prior to start of protocol therapy)
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
Shortening fraction of ≥ 27% by echocardiogram, or
-
Ejection fraction of ≥ 50% by radionuclide angiogram
-
No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months and T-cell count above the lower limit of normal are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
Exclusion Criteria:
-
Patients who received prior radiotherapy to the head or neck
-
Patients who received prior chemotherapy or radiation for the treatment of any cancer in the last 3 years. These patients must also be in remission
-
Patients with a diagnosis of immunodeficiency
-
Patients with an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive agents). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- Note: Patients with well-controlled asthma and no need for systemic steroids for the treatment of asthma in the last 12 months will not be excluded
-
Patients with a condition requiring systemic treatment with either corticosteroids (> 0.25 mg/kg (10 mg) daily prednisone equivalent) within 14 days or other immunosuppressive medications within 30 days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses > 0.25 mg/kg (10 mg) daily prednisone equivalent, are permitted in the absence of active autoimmune disease
-
Patients with a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Patients with detectable viral load of human immunodeficiency virus (HIV), hepatitis B or hepatitis C, or active tuberculosis
-
Patients who have undergone solid organ or allogeneic hematopoietic transplant at any time
-
Due to risks of fetal and teratogenic adverse events as seen in animal studies, a negative pregnancy test must be obtained in females of childbearing potential, defined as females who are post-menarchal. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
-
Females of childbearing potential that are sexually active must agree to either practice 2 medically accepted highly-effective methods of contraception at the same time or abstain from heterosexual intercourse from the time of signing the informed consent through 5 months after the last dose of nivolumab, 6 months after the last dose of gemcitabine, and 14 months after the last dose of cisplatin, whichever is longer
-
Males of childbearing potential that are sexually active must agree to either practice a medically accepted highly-effective methods of contraception or abstain from heterosexual intercourse from the time of signing the informed consent through 3 months after the last dose of gemcitabine, and 11 months after the last dose of cisplatin, whichever is longer
-
Lactating females are not eligible unless they have agreed not to breastfeed their infants starting with the first dose of study therapy through 5 months after the last dose of nivolumab
-
All patients and/or their parents or legal guardians must sign a written informed consent
-
All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Treatment (nivolumab, gemcitabine, cisplatin, radiation)
See Detailed Description |
Ancillary studies
他の名前:
Given IV
他の名前:
Undergo blood sample collection
他の名前:
Undergo CT
他の名前:
Undergo MRI
他の名前:
Ancillary studies Undergo ECHO
他の名前:
Undergo MUGA
他の名前:
Undergo PET
他の名前:
Given IV
他の名前:
Given IV
他の名前:
Undergo tissue biopsy
他の名前:
Undergo chest x-ray
他の名前:
Ancillary studies Receive radiation therapy
他の名前:
Given IV
他の名前:
Undergo dental x-ray
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence of grade 3 or higher immune-related adverse events (irAE) during induction chemoimmunotherapy (CIT)
時間枠:Until the end of consolidation therapy
|
Will be assessed by Common Terminology Criteria for Adverse Events (8th edition). IrAEs include diarrhea (noninfectious), colitis (noninfectious), pneumonitis (noninfectious), myocarditis, elevated alanine aminotransferase, elevated aspartate aminotransferase, pancreatitis, elevated blood bilirubin, hypophysitis and hyperthyroid considered possibly, probably, or definitely related to nivolumab. |
Until the end of consolidation therapy
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event-free survival (EFS)
時間枠:From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
EFS along with the 95% confidence intervals will be estimated using the Kaplan-Meier method. The EFS will be reported separately for patients with non-metastatic disease and those with metastatic disease (if there are enough patients with metastatic disease enrolled). |
From date of enrollment to the earliest occurrence of date of relapse, disease progression, second malignant neoplasm or death due to any cause, assessed at 2 years
|
|
Objective response rate
時間枠:At the end of induction CIT
|
Will be defined as the rate of responders among evaluable patients using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
At the end of induction CIT
|
|
Feasibility success of the induction regimen
時間枠:At the end of induction CIT
|
Will be defined as the completion of three cycles of induction without delay of greater than 30 days for radiation initiation due to toxicity in 80% of patients. |
At the end of induction CIT
|
|
Cumulative incidence of local or distant relapse
時間枠:Up to 5 years
|
Defined as a function of time since enrollment will be estimated by the method of Gray. |
Up to 5 years
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
EFS
時間枠:At 5 years
|
Will be assessed using Kaplan-Meier estimates. |
At 5 years
|
|
Overall survival
時間枠:From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
Will be assessed using Kaplan-Meier estimates. |
From date of enrollment to death due to any cause or date of last follow-up, assessed at 5 years
|
|
Proportion of patients who achieve complete response
時間枠:At the end of induction and maintenance
|
Will be assessed by retrospective central review by the proportion of patients who achieve complete response by magnetic resonance imaging using RECIST 1.1 criteria and the proportion of patients who achieve complete metabolic response using Positron Emission Tomography Response Criteria In Solid Tumors criteria at the end of induction and the end of maintenance based on central review will be presented. A two-way table of response assessments according to the two modalities will be constructed and McNemar's test will be performed to evaluate the concordance. |
At the end of induction and maintenance
|
|
Protocol deviation related to radiation therapy delivery
時間枠:Up to 5 years
|
Will be assessed by retrospective central review. The effect of deviation, categorized as present or absent by the central reviewer, on the hazard of EFS will be estimated by Cox proportional hazard model. The hazard ratio will be reported along with 95% confidence interval. |
Up to 5 years
|
|
EFS in patients receiving intensity modulated radiation therapy with those who receive proton therapy
時間枠:Up to 5 years
|
Will be assessed using a log-rank test. |
Up to 5 years
|
|
Incidence of grade 3 or higher adverse events
時間枠:Up to 5 years
|
Will be assessed during protocol therapy. The incidence of these events will be reported for each toxicity term. Furthermore, the irAE and toxicity related to radiation will be summarized by toxicity term and will be presented separately for the on-protocol therapy period and long-term follow-up. |
Up to 5 years
|
|
Swallowing dysfunction
時間枠:At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using modified Functional Oral Intake Scale (FOIS) and pediatric Eating Assessment Tool (EAT)-10. The EAT-10 consists of 10 items scored from 0 (no impairment) to 4 (severe impairment). Total scores range from 0 to 40; higher scores indicate greater self-perceived impairment. Modified FOIS is an ordinal scale is a rating scale with 7 points for adults and 5 points in pediatrics. It is used to describe the feeding status and patients with dysphagia. Level 1 indicates inability to take anything by mouth while the highest point indicates full oral feeding. Will summarize responses from the modified FOIS and pediatric EAT-10 descriptively for each of these time points. A two-sided Wilcoxon rank-sum test will be performed to test the null hypothesis of equal score between two groups (who receive 54Gy versus 59.4Gy) at the end of the CRIT. Will evaluate the potential impact of other factors, as appropriate, such as baseline scores or disease stages for this analysis. |
At baseline, during induction prior to start of chemoradioimmunotherapy (CRIT), each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Quality of life
時間枠:At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
Will be assessed using Patient-Reported Outcomes Measurement Information System (PROMIS). PROMIS includes multiple measures such as physical function mobility, anxiety, depressive symptoms, fatigue, etc. PROMIS use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation of that population. Higher T-score indicates more of the concept being measured. The numerical T scores of each domain will be summarized descriptively at every time point. |
At baseline, during induction prior to start of CRIT, each cycle throughout CRIT, within 3 months after maintenance and yearly at follow up, up to 5 years
|
|
Lymphocyte-to-monocyte ratio (LMR)
時間枠:At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
Will be assessed the ratio calculated by dividing the absolute lymphocyte count by the absolute monocyte count from a complete blood count with differential analysis performed. Lymphocyte and monocyte counts will be collected at the following time points: baseline, pre-radiation/consolidation, and post-radiation pre-maintenance. Cox proportional hazards regression will be used to evaluate the association between baseline LMR and EFS. The hazard ratio will be reported with a 95% confidence interval. In addition, the LMR will be summarized descriptively by the evaluation time points. |
At baseline, pre-radiation/consolidation, and post-radiation pre-maintenance
|
|
Dental changes
時間枠:At baseline (prior to radiation) and up to 1 post radiation
|
Will include dental caries and osteoradionecrosis. Dental caries will be quantified as the number of teeth with caries, and bone health will be evaluated as a categorical variable using 0 for no disease and a score of 1-4 to match stage of periodontal disease as described in 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions was co-presented by the American Academy of Periodontology and the European Federation of Periodontology staging framework. Changes over time will be evaluated using paired analyses. Given the small sample size, results will primarily be descriptive, with patient's dental caries and bone health data summarized using descriptive statistics. |
At baseline (prior to radiation) and up to 1 post radiation
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Robyn D Gartrell、Children's Oncology Group
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 顎口腔疾患
- 部位別新生物
- 新生物
- 組織型別の新生物
- 頭頸部腫瘍
- 新生物、腺および上皮
- がん
- 耳鼻咽喉科疾患
- 咽頭腫瘍
- 耳鼻咽喉科の新生物
- 上咽頭疾患
- 咽頭疾患
- 上咽頭腫瘍
- 上咽頭がん
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 複素環化化合物、1リング
- 複素環化化合物
- 調査手法
- 治療
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 細胞診断
- 物理現象
- 機器と消耗品
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 無機化学物質
- 塩素化合物
- 窒素化合物
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- 要素
- 金属
- 診断技術、外科的
- 化学技術、分析
- スペクトル分析
- 金属、重い
- プラチナ化合物
- 電磁現象
- 磁気現象
- 遷移要素
- 電磁放射
- 放射、イオン化
- ニボルマブ
- ゲムシタビン
- シスプラチン
- クエン酸1,2-ジアミノシクロヘキサン白金II
- 放射線療法
- 放射線
- 生検
- 標本処理
- 磁気共鳴分光法
- 白金
- X線
- ファントム、イメージング
- フルシクロビンF-18
その他の研究ID番号
その他の研究ID番号
- NCI-2023-07208
- U10CA180886 (米国 NIH グラント/契約)
- NCI-2023-07208 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- ARAR2221 (その他の識別子:CTEP)
- ARAR2221 (その他の識別子:Children's Oncology Group)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。